Weight-based antibiotic dosing in a real-world European study of complicated skin and soft-tissue infections due to methicillin-resistant Staphylococcus aureus

Clinical Microbiology and Infection

Volumn 21, Issue , 2015, Pages S40-S46

  Lawson, W ^a   Nathwani, D ^b   Eckmann, C ^c   Corman, S ^d   Stephens, J ^d   Solem, C ^d   Macahilig, C ^e   Li, J ^f   Baillon Plot, N ^f   Charbonneau, C ^f   Haider, S ^f  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d PHARMERIT INTERNATIONAL   (United States)

^e Medical Data Analytics   (United States)

^f PFIZER INC   (United States)

Author keywords

Complicated skin and soft tissue infection; Daptomycin; Dosing; Methicillin resistant Staphylococcus aureus; Teicoplanin; Vancomycin

Indexed keywords

DAPTOMYCIN; TEICOPLANIN; VANCOMYCIN; ANTIINFECTIVE AGENT;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; DRUG MEGADOSE; FEMALE; HUMAN; KIDNEY FAILURE; LOADING DRUG DOSE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; OBESITY; PRIORITY JOURNAL; SEVERE RENAL IMPAIRMENT; SOFT TISSUE INFECTION; STAPHYLOCOCCAL SKIN INFECTION; ADOLESCENT; AGED; BODY WEIGHT; COMPLICATION; DIABETES MELLITUS; EUROPE; INTRAVENOUS DRUG ADMINISTRATION; ISOLATION AND PURIFICATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MIDDLE AGED; PERIPHERAL VASCULAR DISEASE; RETROSPECTIVE STUDY; SOFT TISSUE INFECTIONS; STAPHYLOCOCCAL SKIN INFECTIONS; VERY ELDERLY; YOUNG ADULT;

ADMINISTRATION, INTRAVENOUS; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BODY WEIGHT; DAPTOMYCIN; DIABETES COMPLICATIONS; EUROPE; FEMALE; HUMANS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MIDDLE AGED; PERIPHERAL VASCULAR DISEASES; RETROSPECTIVE STUDIES; SOFT TISSUE INFECTIONS; STAPHYLOCOCCAL SKIN INFECTIONS; TEICOPLANIN; VANCOMYCIN; YOUNG ADULT;

EID: 84942295144     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1016/j.cmi.2015.05.030     Document Type: Article

References (16)

1. Esposito S., Bassetti M., Borre S., Bouza E., Dryden M., Fantoni M., et al. Diagnosis and management of skin and soft-tissue infections (SSTI): a literature review and consensus statement on behalf of the Italian Society of Infectious Diseases and International Society of Chemotherapy. J Chemother 2011, 23:251-262.
2. Vancomycin [summary of product characteristics] 2012, Sandoz, Frimley, Camberley, Surrey, UK.
3. Liu C., Bayer A., Cosgrove S.E., Daum R.S., Fridkin S.K., Gorwitz R.J., et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis 2011, 52:285-292.
4. Vance-Bryan K., Guay D.R., Gilliland S.S., Rodvold K.A., Rotschafer J.C. Effect of obesity on vancomycin pharmacokinetic parameters as determined by using a Bayesian forecasting technique. Antimicrob Agents Chemother 1993, 37:436-440.
5. Blouin R.A., Bauer L.A., Miller D.D., Record K.E., Griffen W.O. Vancomycin pharmacokinetics in normal and morbidly obese subjects. Antimicrob Agents Chemother 1982, 21:575-580.
6. ® Outcomes Registry and Experience (EU-CORE). 20th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2010, Vienna, Austria.
7. Eckmann C., Lawson W., Nathwani D., Solem C.T., Stephens J.M., Macahilig C., et al. Antibiotic treatment patterns across Europe in patients with complicated skin and soft-tissue infections due to methicillin-resistant Staphylococcus aureus: a plea for implementation of early switch and early discharge criteria. Int J Antimicrob Agents 2014, 44:56-64.
8. Lawson W., Nathwani D., Eckmann C., Stephens J., Macahilig C., Solem C., et al. Antibiotic treatment patterns across Europe for complicated skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus. 23rd European Congress of Clinical Microbiology and Infectious Diseases Meeting 2013, Berlin, Germany.
9. Nathwani D., Eckmann C., Lawson W., Stephens J.M., Macahilig C., Solem C.T., et al. Pan-European early switch/early discharge opportunities exist for hospitalized patients with methicillin-resistant Staphylococcus aureus complicated skin and soft tissue infections. Clin Microbiol Infect 2014, 20:993-1000.
10. Targocid [summary of product characteristics] 2010, Sanofi, Guildford, Surrey, UK.
11. Cubicin [summary of product characteristics] 2012, Novartis, Frimley, Camberley, Surrey, UK.
12. Targocid [summary of product characteristics] 2013, Sanofi, Guildford, Surrey, UK.
13. Rybak M., Lomaestro B., Rotschafer J.C., Moellering R., Craig W., Billeter M., et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health-Syst Pharm 2009, 66:82-98.
14. Matthews P.C., Chue A.L., Wyllie D., Barnett A., Isinkaye T., Jefferies L., et al. Increased teicoplanin doses are associated with improved serum levels but not drug toxicity. J Infect 2014, 68:43-49.
15. Arbeit R.D., Maki D., Tally F.P., Campanaro E., Eisenstein B.I., Daptomycin, et al. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 2004, 38:1673-1681.
16. Fowler V.G., Boucher H.W., Corey G.R., Abrutyn E., Karchmer A.W., Rupp M.E., et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by staphylococcus aureus. N Engl J Med 2006, 355:65365.